Journal of Clinical Oncology
Articles in this Issue
Combining low-dose regorafenib with pembrolizumab as a front-line therapy for patients with MSI-H colorectal cancer: REGPEM-CRC-01.
TPS3643 Background: Currently, pembrolizumab is one of the front-line therapies for patients with MSI-H CRC. However, approximately 40% of patients who re...
Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+/HER2− metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D).
1020 Background: PF-07248144 is a selective catalytic inhibitor of KAT6, a histone lysine acetyltransferase. To inform the RP3D, we evaluated two pharmaco...
YAP1 and downstream gene alterations in metastatic breast cancer.
e13121 Background: Metastatic breast cancer remains a major clinical challenge, characterized by poor prognosis and limited therapeutic options. The incid...
Evaluating lung cancer clinical characteristics and tumor subtypes using cell-free DNA fragmentomes.
8074 Background: Liquid biopsies provide an opportunity for non-invasive lung cancer detection and tumor subtyping when tumor tissue is not available. Her...
Temporal and regional mortality trends due to pulmonary embolism in female patients with genital cancers in the United States from 1999 to 2020.
5617 Background: The involvement of pulmonary vessels by tumor emboli has been described from different primary sites of malignancy. Pulmonary embolism (P...
Interpretable artificial intelligence-driven selection of doublet chemotherapy regimens as second-line treatment in patients with advanced pancreatic cancer.
4171 Background: Guidelines recommend second-line (2L) doublet chemotherapy, NALIRI (liposomal irinotecan + 5-fluoruracil and leucovorin), FOLFIRI or FOLF...
Digital spatial profiling for identification of prognostic genes and molecular subgroups in pleural mesothelioma.
8084 Background: Pleural mesothelioma (PM) is an aggressive malignancy that harbors significant inter- and intra-tumoral heterogeneity. Spatial transcript...
Validation of LungFlag Lean machine-learning model to identify individuals with lung cancer using multinational data.
e13649 Background: Lung cancer (LC) is the leading cause of cancer-related deaths worldwide. Risk prediction models developed to identify elevated risk po...
Real-world impact of trastuzumab-based therapy in HER2-positive advanced gastric cancer: Evidence from a Latin American cancer center.
e16093 Background: Gastric cancer ranks as the fifth leading cause of cancer-related mortality worldwide. HER2-positive cases represent 10–20% of gastric...
Risk assessment of thyroiditis in patients undergoing chimeric antigen receptor T-cell therapy: A retrospective cohort analysis.
e14523 Background: The introduction of immunotherapy in oncology has increased the risk of immune-immediate adverse effect. Chimeric antigen receptor T-ce...
Ceralasertib (cerala) + olaparib (ola) in patients (pts) with homologous recombination repair (HRR)-deficient platinum-sensitive relapsed ovarian cancer (OC) after progression on prior PARP inhibitor (PARPi) treatment (tx).
5542 Background: Combining an ATR inhibitor (ATRi) and a PARPi may overcome acquired PARPi resistance based on preclinical and clinical data. We report a...
Gender, place of death, and racial disparities in the reporting odds ratio of cardiovascular disease burden in leukemia across age groups (15–85) in the U.S.: A CDC WONDER disproportionality analysis.
1535 Background: Leukemia, a hematologic malignancy, often coexists with cardiovascular disease (CVD), worsening outcomes due to shared risk factors like...
Insights into disease progression in endometrial cancers: The role of cell proliferation pathway mutations following adjuvant therapy.
e17633 Background: Endometrial cancer, a common malignancy of the uterine lining, is typically treated with through hysterectomy. Mutations in cell prolif...
Leveraging electronic medical records for early lung cancer diagnosis: An evaluation of the C the Signs AI cancer prediction platform using the Mayo data platform.
8053 Background: In the US, only 27.4% of lung cancer cases are diagnosed early, with 5-year survival rates of 63% for localized and 27% for late-stage ca...
The safety and efficacy of selective internal radiation therapy for hepatocellular carcinoma: A retrospective study in China.
e16311 Background: The significance of selective internal radiation therapy with yttrium-90 resin microspheres ( 90 Y-SIRT) is wid...
A phase 1 study of B7H3 CAR-T cells administered intracranially in recurrent glioblastoma.
2018 Background: Glioblastoma (GBM) is an aggressive malignancy with median survival of approximately 2 years from initial diagnosis and 9 months after fi...
Guard-02: Safety and efficacy of prophylactic use of novel long-acting G-CSF efbemalenograstim α on same-day of chemotherapy in breast cancer patients.
e24088 Background: Granulocyte colony-stimulating factor (G-CSF) is widely used for prevention of chemotherapy-induced neutropenia (CIN), there is controv...
Use of artificial intelligence–assistance software for HER2-low and HER2-ultralow IHC interpretation training to improve diagnostic accuracy of pathologists and expand patients' eligibility for HER2-targeted treatment.
1014 Background: The advent of HER2-targeted antibody-drug conjugates and the introduction of HER2-low and HER2-ultralow diagnostic categories have made p...
Prognostic value of PSMA radio-genomics in hormone sensitive synchronous metastatic prostate cancer.
e17116 Background: Molecular characterization of prostate cancer (PCa) has allowed development in targeted therapies design; with molecular imaging as PSM...
Needed leaders and leaders’ needs: The creation of a quality improvement and clinical operations pathway for heme/onc fellows.
e21008 Background: The Accreditation Council for Graduate Medical Education requires training programs to provide education on quality improvement and pat...
Survival outcomes of stages II-IV gastric cancer: A 13-year single center experience.
e16091 Background: The management of locoregional and metastatic gastric cancers (Ga-Ca) has significantly changed, particularly with the introduction of...
A pooled analysis of JSKN003, a biparatopic anti-HER2 antibody conjugate (ADC), in patients with advanced HER2-overexpressing (IHC 3+) gastrointestinal tumors.
3022 Background: JSKN003 is a biparatopic HER2-targeting ADC conjugated with a topoisomerase I inhibitor (TOP1i) payload via a dibenzocylooctyne tetrapept...
Efficacy and safety of tazemetostat in patients with refractory/relapsed follicular lymphoma or diffuse large B cell lymphoma: Systematic review and meta analysis.
e19064 Background: Around 20-25% of individuals diagnosed with follicular lymphoma (FL) do not respond to the first line of treatment. There has been no c...
Multimodal thermal therapy to promote the expansion of tumor-reactive–like CX3CR1 <sup>+</sup> GPR56 <sup>+</sup> T cells in hepatocellular carcinoma patients.
e16286 Background: Local ablation represents the minimal treatment option for patients with hepatocellular carcinoma (HCC) who cannot be treated with surg...
Efficacy and safety of FOLFIRINOX versus gemcitabine-based regimens for treatment of metastatic pancreatic cancer: A systematic review and meta-analysis.
e16393 Background: Metastatic pancreatic cancer (MPC) is an aggressive malignancy with limited treatment options. FOLFIRINOX, a combination regimen of fol...